⚠ The Clock Is Always RunningModerate threat

Every patent monopoly comes with a countdown, and the day it reaches zero the drug that earned billions becomes a commodity almost overnight. Once a small-molecule drug's patent lapses, generic makers flood in, and the price can fall by eighty or ninety percent within a year — the revenue simply evaporates. This is not a risk that might materialize; it is a certainty on a known schedule, built into the very nature of the moat, and it hangs over every one of Lilly's blockbusters.

The danger is that the loss is sudden, large, and predictable in timing but not always in magnitude. When a major drug goes off patent, a company can lose a substantial fraction of its revenue in a single stroke, and if too many patents expire close together, the cliff can be severe enough to reshape the whole business. Lilly has been through this before — the loss of exclusivity on past blockbusters forced painful stretches — and it will face it again with today's winners in the 2030s and beyond.

Lilly manages the clock the only way any drugmaker can: by racing to invent new patented drugs faster than the old ones expire, and by lifecycle strategies that extend protection where possible. Its extraordinary current pipeline is, in large part, exactly this race being run. But an owner should never forget that the patent moat is temporary by law, that the erosion when it comes is brutal and swift, and that Lilly's entire enterprise depends on out-inventing its own expiration dates — a race it must win continuously, as the orforglipron and retatrutide programs are meant to prove¹.